BI-PEGLYTE 1.46 G
SODIUM CHLORIDE : 1.46 G POTASSIUM CHLORIDE : 0.76 G SODIUM BICARBONATE : 1.69 G POLYETHYLENE GLYCOL 3350 : 59.55 G BISACODYL : 5 MG SODIUM SULFATE : 5.74 G · DIN 02326302 · PENDOPHARM DIVISION OF PHARMASCIENCE INC
Health Canada status: MARKETED
What is BI-PEGLYTE?
BI-PEGLYTE 1.46 G contains SODIUM CHLORIDE : 1.46 G POTASSIUM CHLORIDE : 0.76 G SODIUM BICARBONATE : 1.69 G POLYETHYLENE GLYCOL 3350 : 59.55 G BISACODYL : 5 MG SODIUM SULFATE : 5.74 G. It is listed in the Health Canada Drug Product Database under DIN 02326302, held by PENDOPHARM DIVISION OF PHARMASCIENCE INC, supplied as KIT ; POWDER FOR SOLUTION ; TABLET (DELAYED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 06-Jun-2010. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02326302 |
|---|---|
| Brand name | BI-PEGLYTE |
| Generic / active ingredient | SODIUM CHLORIDE : 1.46 G POTASSIUM CHLORIDE : 0.76 G SODIUM BICARBONATE : 1.69 G POLYETHYLENE GLYCOL 3350 : 59.55 G BISACODYL : 5 MG SODIUM SULFATE : 5.74 G |
| Manufacturer | PENDOPHARM DIVISION OF PHARMASCIENCE INC |
| Strength | 1.46 G |
| Dosage form | KIT ; POWDER FOR SOLUTION ; TABLET (DELAYED-RELEASE) |
| Route of administration | ORAL |
| Schedule | Ethical |
| ATC code | A06AB52 BISACODYL, COMBINATIONS |
| AHFS class | 56:12.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 06-Jun-2010 |
| Original market date | 2010-06-06 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code A06AB52 BISACODYL, COMBINATIONS. 2 of 4 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| JAMPLYTE + BISACODYL | 1.69 G | POWDER FOR SOLUTION ; KIT ; TABLET (DELAYED-RELEASE) | JAMP PHARMA CORPORATION | MARKETED | DIN 02552612 |
| FRUITATIVES ECT | 12.5 MG | TABLET (ENTERIC-COATED) | ROGERS PHARMACEUTICALS LTD. | CANCELLED POST MARKET | DIN 00361690 |
| GENTLAX S | 5 MG | TABLET | PURDUE PHARMA | CANCELLED POST MARKET | DIN 02252872 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.